We are happy to announce that we will exhibit again during the 33rd Annual European Association of Nuclear Medicine Congress, which will take place in Vienna, from 17 to 21 October 2020. You can already contact our team to make an appointment!
We will also have the opportunity to meet you in September during the next JFMN (Journée Francophones de Médecine Nucléaire) organized in Paris, and during the CSH (Convergences Santé Hôpital) organized in Nantes in October.
The SNMMI is already over, time flew by fast ! We were so happy to meet you there.
The show went great this year, we ended up with a lot of promising projects. The FDA approval of Trasis FDOPA's process was among other the icing of the cake.
If you missed us but would like to get updated on Trasis' products, feel free to contact us.
Our team will be delighted to meet you at the ISRS in Beijing this year.
You can make an appointment or meet us on our booth.
The EANM already seems so far away... We really miss the intensity of having a booth full of people every single day! This edition might be over on the paper but it is still running through our heads. We then couldn't resist to share some of the best moments with you.
Düsseldorf, 15 October 2018 : Trasis' Community Meeting.
Düsseldorf, 15 October 2018.
Prostate cancer is the second leading cause of cancer death for men in many parts of the world. For imaging, PSMA-based radio tracers target the PSMA (Prostate Specific Membrane Antigen) transmembrane glycoprotein, which is strongly upregulated in prostate cancer cells. In this way, the PET tracer provides important molecular information on cancer and metastases localization within the prostate.
AllinOne family versatility proven
Three months after its approval by the American FDA, Trasis’ FDG Dual method obtains its Market Authorization for Belgium and the Netherlands.
Trasis and Radboud Translational Medicine (RTM) worked together and finalized the Marketing Authorization National Phase for FDG production on AllinOne synthesizers.
